I'm LongbridgeAI, I can summarize articles.Bank of America Securities analyst Koichi Mamegano reiterated a Buy rating on Takeda Pharmaceutical with a Yen6,000 price target. The decision follows Takeda's strong Q1 performance, where revenue and core operating profit beat forecasts due to favorable FX effects. Management is advancing a late-stage pipeline and executing the Horizon One strategy for long-term growth. Jefferies also maintained a Buy rating with a Yen6,800 target.
Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co. The associated price target is Yen6,000.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Koichi Mamegano has given his Buy rating due to a combination of factors, including Takeda’s solid first-quarter delivery relative to market expectations. Revenue and core operating profit both surpassed consensus forecasts by mid‑single to low‑teens percentages, driven largely by favorable foreign‑exchange effects, while underlying performance at constant currency remained broadly stable, supporting his unchanged price objective.
Core franchises are largely performing in line with plans, and management is advancing a late‑stage pipeline that could add meaningful U.S. growth via three expected launches over the next two fiscal years. Coupled with the Horizon One strategy, which focuses on defending key products, extracting value from pipeline assets, and boosting efficiency across the company, Mamegano views Takeda as building a credible platform for medium‑ to long‑term earnings expansion that justifies a Buy stance.
In another report released on July 28, Jefferies also maintained a Buy rating on the stock with a Yen6,800.00 price target.